NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Going after low-grade glioma market as well?

4:25-4:30pm [November 18, 2016] Phase IIa clinical trial evaluating dendritic cell ATIM-32 vaccine for the treatment of low-grade
gliomas
Moughon D, Everson R, Odesa S, Soto H, Billingslea-Yoon E, Sedighim S, Orpilla J, Lin J, Prins R, Liau L -- Abstract to be presented at SNO conference, November 18, 2016.

http://www.soc-neuro-onc.org/media/files/files/d4715a5a/2016_SNO_Meeting_Preliminary_Program.pdf

Here is the associated clinical trial.

The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors. https://clinicaltrials.gov/ct2/show/NCT01635283

Remember, through hospital exemption, in Germany DCVax-L is approved to treat lower grade glioma as well.